Controlled comparison of amikacin and gentamicin

Area of Science:

• Clinical Pharmacology
• Infectious Diseases
• Nephrology
• Otolaryngology

Background:

• Severe gram-negative infections pose significant therapeutic challenges.
• Aminoglycosides like amikacin and gentamicin are crucial for treating these infections.
• Comparative efficacy and toxicity data are essential for clinical decision-making.

Purpose of the Study:

• To compare the efficacy of amikacin versus gentamicin in patients with severe gram-negative infections.
• To evaluate and compare the nephrotoxicity and auditory toxicity of amikacin and gentamicin.

Main Methods:

• Prospective, randomized, double-blind clinical trial involving 174 patients.
• Patients received either amikacin or gentamicin for suspected severe gram-negative infections.
• Efficacy and toxicity (nephrotoxicity, ototoxicity) were assessed and compared between treatment groups.

Main Results:

• Overall favorable response rates were similar: 77% for amikacin and 78% for gentamicin.
• Amikacin demonstrated effectiveness across various infection types, including bacteremia and urinary tract infections.
• No statistically significant differences in definite nephrotoxicity (8% amikacin vs. 11% gentamicin) or ototoxicity (6% amikacin vs. 10% gentamicin) were observed.

Conclusions:

• Amikacin is an effective therapeutic option for severe gram-negative infections.
• Amikacin exhibits comparable efficacy and toxicity profiles to gentamicin.
• The study indicates no significant difference in ototoxicity or nephrotoxicity between amikacin and gentamicin.